Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2023 Debates and Didactics in Hematology and Oncology Conference
IASLC 2023 World Conference on Lung Cancer
2023 ASCO Breakthrough Meeting
EHA Hybrid Congress 2023
ESMO Breast Cancer Annual Congress 2023
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
SGO 2023 Annual Meeting on Women���s Cancer
«
1
»
Advertisement
Advertisement
Oct
02
Today In Oncology
Relapsed or Refractory Multiple Myeloma Mezigdomide Plus Dexamethasone
Allogeneic HCT Outcomes in Patients With MDS and High-Risk Genetics
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
Prophylactic Radiation for High-Risk Asymptomatic Bone Metastases
View More
Advertisement
